The California Life Sciences team advised Reverie Labs on its $25 million Series A financing. This financing brings the total capital raised by Reverie to more than $32 million.
Reverie is a pharmaceutical company pioneering the application of machine learning to developing next-generation kinase inhibitors.
Reverie will use the proceeds to advance its internal and partnered drug discovery programs towards the clinic, further develop its best in class computational discovery platform, and grow its world-class, cross-disciplinary team of scientists.
The Goodwin team was led by Deepa Rich and Craig Schmitz with support from Shoaib Ghias.
For more details, read the press release and articles in Endpoints and VentureBeat.